Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3–5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol

• DOI: 10.2214/ajr.14.14268
• Publication Date: 2015-08-21T15:15:19Z
• Authors: Gilles Soulez; Daniel C. Bloomga...; Neil M. Rofsky; Martin P. Smith; Hani H. Abujudeh; Desiree E. Morgan; Richard J. Lichte...; Mark L. Schiebler; Franz J. Wippold; Craig Russo; Matthew J. Kuhn; Kevin W. Mennitt; Jeffrey H. Maki; Alan Stolpen; Johnson Liou; Richard C. Semelka; Miles A. Kirchin; Ningyan Shen; Gianpaolo Pirovano; Alberto Spinazzi
• Keywords: Nephrogenic Systemic Fibrosis

OBJECTIVE. The purpose of this study was to determine the incidence nephrogenic systemic fibrosis (NSF) in patients with chronic kidney disease (CKD) and moderate-to-severe impairment function who had not previously been exposed gadolinium-based contrast agents (GBCAs) or referred undergo contrast-enhanced MRI gadobenate dimeglumine gadoteridol.